Adimmune COVID-19 Vaccine Production Team Welcomes JHL Biotech, Inc

Adimmune Biotech Corporation(4142) announced today that it has signed a Master Service Agreement with one of Taiwan’s major Bio-pharmaceutical manufacturers, JHL Biotech,Inc.

In addition to its own production capability, by  joining forces with JHL Biotech, Inc. and Mycenax Biotech, Inc, Adimmune believes its annual production will satisfy Taiwan’s needs for the COVID-19 vaccine. Adimmune pointed out that in order to comply with the government’s preventive requirements, it is committed to supply the vaccine locally first. Locating and cooperating with local partners established a downstream production chain, and laid the foundation for Taiwan’s Biotechnical industry towards globalization.